ES2654847T3 - Compuestos de benzoxazol y benzotiazol sustituidos en 6-O y métodos para inhibir la señalización CSF-1R - Google Patents

Compuestos de benzoxazol y benzotiazol sustituidos en 6-O y métodos para inhibir la señalización CSF-1R Download PDF

Info

Publication number
ES2654847T3
ES2654847T3 ES07797244.6T ES07797244T ES2654847T3 ES 2654847 T3 ES2654847 T3 ES 2654847T3 ES 07797244 T ES07797244 T ES 07797244T ES 2654847 T3 ES2654847 T3 ES 2654847T3
Authority
ES
Spain
Prior art keywords
benzo
yloxy
thiazol
cyclohexanol
lamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07797244.6T
Other languages
English (en)
Inventor
James C. Sutton
Marion Wiesmann
Weibo Wang
Mika K. Lindvall
Jiong Lan
Savithri Ramurthy
Anu Sharma
Elizabeth J. Mieuli
Liana M. Klivansky
William P. Lenahan
Susan Kaufman
Hong Yang
Simon C. Ng
Keith Pfister
Allan Wagman
Victoria Sung
Martin Sendzik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2654847T3 publication Critical patent/ES2654847T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Un compuesto seleccionado de entre el grupo que consiste en**Tabla** o un estereoisómero, tautómero, solvato, u óxido, o sal derivada del mismo farmacéuticamente aceptable.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
Esquema 4 de referencia
imagen17
En el esquema 4 de referencia, 3-(2-piperidin-1-il-etil)-fenilamina es un ejemplo de una amina que puede ser usada para formar un compuesto de los Ejemplos o Ejemplos de referencia. 3-(2-piperidin-1-il-etil)-fenilamina es formada por la sulfonación de 2-(3-nitrofenil)-etanol, luego introducción de amina en el 2-(3-nitrofenil)etil éster de ácido metanosulfónico resultante, y a continuación reducción de la 1-[2-(3-nitrofenil)-etil]-piperidina resultante.
Esquema 5 de referencia
imagen18
En el esquema 5 de referencia, con ciclohexilmetanamina se introduce amina en 4-(2-(metilsulfinil)benzo[d]oxazol
10 6-iloxi)-N-metilpiridin-2-carboxamida. La 4-(2-(ciclohexilmetilamino)benzo[d]oxazol-6-iloxi)-N-metilpiridin-2carboxamida resultante es entonces hidrolizada para formar ácido 4-[2-(ciclohexilmetil-amino)-benzooxazol-6-iloxi]piridin-2-carboxílico. El ácido 4-[2-(ciclohexilmetil-amino)-benzooxazol-6-iloxi]-piridin-2-carboxílico reacciona entonces con hexafluorofosfato de benzotriazol-1-iloxitris(dimetilamino)-fosfonio, tert-butil carbazato, y trietil amina para formar 4-(2-(ciclohexilmetilamino) benzo[d]oxazol-6-iloxi)piridin-2-carbohidrazida. La 4-(2
15 (ciclohexilmetilamino)benzo[d]oxazol-6-iloxi)piridin-2-carbohidrazida reacciona entonces con trimetil ortoformiato para formar un compuesto de los Ejemplos o Ejemplos de referencia.
Esquema 6 de referencia
imagen19
18
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29
imagen30
imagen31
imagen32
imagen33
imagen34
imagen35
imagen36
imagen37
imagen38
imagen39
imagen40
Tabla 3
Comp.
Prep Ej. Estructura Nombre (M+H)+, Tr (min.)
7
201 imagen41 4-(2-((1R,2R)-2hidroxiciclohexilamino)benzo[d]oxazol6-iloxi)-N-metilpicolinamida 383, 1.96
10
171 imagen42 4-(2-((1R,2R)-2hidroxiciclohexilamino)benzo[d]tiazol-6iloxi)-N,Ndimetilpicolinamida 413.1, 1.87
11
171 N-ciclopropil-4-(2-((1R,2R)-2hidroxiciclohexilamino)benzo[d]tiazol-6iloxi)picolinamida 425.2, 2.13
12
171 imagen43 4-(2-((1R,2R)-2hidroxiciclohexilamino)benzo[d]tiazol-6iloxi)-N-(tetrahidro-2H-piran-4il)picolinamida 469.2, 2.09
13
171 imagen44 4-(2-((1R,2R)-2hidroxiciclohexilamino)benzo[d]tiazol-6iloxi)-N-(1-metilpiperidin-4il)picolinamida 482.2, 1.85
14
171 4-(2-((1R,2R)-2hidroxiciclohexilamino)benzo[d]tiazol-6iloxi)-N-(1-metilpiperidin-3il)picolinamida 482.2, 1.87
15
171 imagen45 N-(2-acetamidoetil)-4-(2-((1R,2R)-2hidroxiciclohexilamino)benzo[d]tiazol6-iloxi)picolinamida 470.2, 1.86
16
171 imagen46 4-(2-((1R,2R)-2hidroxiciclohexilamino)benzo[d]tiazol6-iloxi)-N-(2-(pirrolidin-1il)etil)picolinamida 482.2, 1.84
17
171 imagen47 4-(2-((1R,2R)-2hidroxiciclohexilamino)benzo[d]tiazol6-iloxi)-N-((tetrahidrofuran-2il)metil)picolinamida 469.2, 2.16
18
171 imagen48 4-(2-((1R,2R)-2hidroxiciclohexilamino)benzo[d]tiazol6-iloxi)-N-((tetrahidro-2H-piran-4il)metil)picolinamida 483.2, 2.12
40
(cont.)
Comp.
Prep Ej. Estructura Nombre (M+H)+, Tr (min.)
19
171 imagen49 4-(2-((1R,2R)-2hidroxiciclohexilamino)benzo[d]tiazol6-iloxi)-N-((1-metilpiperidin-4il)metil)picolinamida 496.2, 1.84
20
171 imagen50 N-(((S)-1-etilpirrolidin-2-il)metil)-4-(2((1R,2R)-2hidroxiciclohexilamino)benzo[d]tiazol6-iloxi)picolinamida 496.2, 1.88
47
171 imagen51 N-etil-4-(2-((1R,2R)-2hidroxiciclohexilamino)benzo[d]tiazol6-iloxi)picolinamida 413.2, 2.09
48
171 imagen52 4-(2-((1R,2R)-2hidroxiciclohexilamino)benzo[d]tiazol6-iloxi)-N-(2,2,2trifluoroetil)picolinamida 467.1, 2.37
49
171 imagen53 4-(2-((1R,2R)-2hidroxiciclohexilamino)benzo[d]tiazol6-iloxi)-N-propilpicolinamida 427.1, 2.25
50
171 imagen54 N-(ciclopropilmetil)-4-(2-((1R,2R)-2hidroxiciclohexilamino)benzo[d]tiazol6-iloxi)picolinamida 439.2, 2.32
51
171 imagen55 4-(2-((1R,2R)-2hidroxiciclohexilamino)benzo[d]tiazol6-iloxi)-N-isopropilpicolinamida 427.2, 2.24
125
162 imagen56 4-(2-((1r,4r)-4hidroxiciclohexilamino)benzo[d]tiazol6-iloxi)-N-metilpicolinamida 399.1, 1.83
155
175 imagen57 (1R,2R)-2-(6-(2-(1-metil-1H-imidazol2-il)piridin-4-iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 422.1, 1.83
41
(cont.)
Comp.
Prep Ej. Estructura Nombre (M+H)+, Tr (min.)
156
175 imagen58 (1R,2R)-2-(6-(2-(pirazin-2-il)piridin-4iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 420.1, 1.91
157
175 imagen59 (1R,2R)-2-(6-(2-(tiazol-5-il)piridin-4iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 425.0, 2.05
158
175 imagen60 (1R,2R)-2-(6-(2-(1-metil-1H-imidazol5-il)piridin-4-iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 422.1, 1.84
159
175 imagen61 (1R,2R)-2-(6-(2-(tiazol-4-il)piridin-4iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 425.0, 1.85
160
175 imagen62 (1R,2R)-2-(6-(2-(tiazol-2-il)piridin-4iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 425.0, 2.28
161
188 imagen63 (1R,2R)-2-(6-(2-(1,2,3,6tetrahidropiridin-4-il)piridin-4iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 423.1, 1.38
162
177 (1R,2R)-2-(6-(2-(5-etil-4-metil-1Himidazol-2-il)piridin-4iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 450.1, 1.82
164
174 (1R,2R)-2-(6-(6’-(4-metilpiperazin-1-il)2,3’-bipiridin-4-iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 517.2, 1.75
42
(cont.)
Comp.
Prep Ej. Estructura Nombre (M+H)+, Tr (min.)
165
174 (1R,2R)-2-(6-(6’-morfolino-2,3’-bipiridin4-iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 504.1, 1.93
166
174 (1R,2R)-2-(6-(2-(3(morfolinometil)fenil)piridina-4iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 517.1, 1.78
167
174 (1R,2R)-2-(6-(2-ciclohexenilpiridin-4iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 422.1, 2.07
168
174 (1R,2R)-2-(6-(2-(4(morfolinometil)fenil)p yridin-4iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 517.2, 1.76
169
174 (1R,2R)-2-(6-(2-ciclopropilpiridin-4iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 382.1, 1.84
170
174 (1R,2R)-2-(6-(6’-metoxi-2,3’-bipiridin-4iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 449.1, 1.98
171
174 (1R,2R)-2-(6-(2’-fluoro-2,4’-bipiridin-4iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 437.1, 2.22
172
174 (1R,2R)-2-(6-(3’-fluoro-2’-morfolino-2,4’bipiridin-4-iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 522.2, 2.17
173
174 (1R,2R)-2-(6-(6’-fluoro-2,3’-bipiridin-4iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 437.1, 2.04
43
(cont.)
Comp.
Prep Ej. Estructura Nombre (M+H)+, Tr (min.)
174
183 (1R,2R)-2-(6-(2-(piperidin-1-il)piridin-4iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 425.1, 1.98
175
183 (1R,2R)-2-(6-(2-morfolinopiridin-4iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 427.1, 1.80
176
183 (1R,2R)-2-(6-(2-(4-metilpiperazin-1il)piridin-4-iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 440.1, 1.66
177
183 N-((R)-1-(4-(2-((1R,2R)-2hidroxiciclohexilamino)benzo[d]tiazol-6iloxi)piridin-2-il)pirrolidin-3-il)acetamida 468.1, 1.78
178
183 N-((S)-1-(4-(2-((1R,2R)-2hidroxiciclohexilamino)benzo[d]tiazol-6iloxi)piridin-2-il)pirrolidin-3-il)acetamida 468.1, 1.77
179
183 4-(4-(2-((1R,2R)-2hidroxiciclohexilamino)benzo[d]tiazol-6iloxi)piridin-2-il)piperazin-2-one 440.1, 1.70
180
175 (1R,2R)-2-(6-(2,2’-bipiridin-4iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 419.0, 1.87
181
175 (1R,2R)-2-(6-(2-(1-metil-3(trifluorometil)-1H-pirazol-5-il)piridin-4iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 490.1, 2.60
44
(cont.)
Comp.
Prep Ej. Estructura Nombre (M+H)+, Tr (min.)
182
174 (1R,2R)-2-(6-(2-(1-(2-morfolinoetil)-1Hpirazol-4-il)piridin-4-iloxi)benzo[d]tiazol2-ilamino)ciclohexanol 521.1, 1.71
184
192 (1R,2R)-2-(6-(6,7-dimetoxiquinolin-4iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 452.1, 2.00
185
176 (1R,2R)-2-(6-(2-(1-etil-1H-pirazol-4il)piridin-4-iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 436.0, 1.89
186
176 (1R,2R)-2-(6-(2-(1-(2-(dietilamino)etil)1H-pirazol-4-il)piridin-4iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 507.1, 1.75
187
176 (1R,2R)-2-(6-(2-(1-(2,2-difluoroetil)-1Hpirazol-4-il)piridin-4-iloxi)benzo[d]tiazol2-ilamino)ciclohexanol 472.0, 1.90
188
179 (1R,2R)-2-(6-(3-(1H-pirazol-4-il)piridin4-iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 408.1, 1.70
189
179 (1R,2R)-2-(6-(3-(1-metil-1H-pirazol-4il)piridin-4-iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 422.1, 1.79
45
(cont.)
Comp.
Prep Ej. Estructura Nombre (M+H)+, Tr (min.)
190
179 (1R,2R)-2-(6-(3,3’-bipiridin-4iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 419.1, 1.66
191
179 (1R,2R)-2-(6-(3-(1-metil-1H-pirazol-5il)piridin-4-iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 422.1, 1.83
192
179 (1R,2R)-2-(6-(3,4’-bipiridin-4iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 419.1, 1.61
193
179 (1R,2R)-2-(6-(6’-amino-3,3’-bipiridin-4iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 434.1, 1.60
194
179 (1R,2R)-2-(6-(6’-(4-metilpiperazin-1-il)3,3’-bipiridin-4-iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 517.2, 1.64
195
179 (1R,2R)-2-(6-(3-ciclopropilpiridin-4iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 382.1, 1.97
196
174 (1R,2R)-2-(6-(2-(2-morfolinopirimidin-5il)piridin-4-iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 505.1, 2.03
46
(cont.)
Comp.
Prep Ej. Estructura Nombre (M+H)+, Tr (min.)
197
174 (1R,2R)-2-(6-(2-(4-(4-metilpiperazin-1il)fenil)piridin-4-iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 516.2, 1.85
200
177 (1R,2R)-2-(6-(2-(4-(trifluorometil)-1Himidazol-2-il)piridin-4iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 476.1, 2.35
203
192 (1R,2R)-2-(6-(2-metilpiridin-4iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 356.1, 1.73
209
192 (1R,2R)-2-(6-(3-fluoropiridin-4iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 360.1, 1.83
224
178 (1R,2R)-2-(6-(3-bromopiridin-4iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 420.1/42 2.0, 1.81
225
173 (1R,2R)-2-(6-(2-chloropiridin-4iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 376.1, 2.13
226
173 4-(2-((1R,2R)-2hidroxiciclohexilamino)benzo[d]tiazol-6iloxi)picolinonitrile 367.1, 2.03
231
177 (1R,2R)-2-(6-(2-(4-metil-1H-imidazol-2il)piridin-4-iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 422.1, 1.88
47
(cont.)
Comp.
Prep Ej. Estructura Nombre (M+H)+, Tr (min.)
232
177 (1R,2R)-2-(6-(2-(4,5-dimetil-1Himidazol-2-il)piridin-4iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 436.1, 1.93
258
177 (1R,2R)-2-(6-(2-(4,5,6,7-tetrahidro-1Hbenzo[d]imidazol-2-il)piridin-4iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 462.2, 2.03
259
176 (1R,2R)-2-(6-(2-(1-(2-fluoroetil)-1Hpirazol-4-il)piridin-4-iloxi)benzo[d]tiazol2-ilamino)ciclohexanol 454.2, 1.89
260
176 (1R,2R)-2-(6-(2-(1-(2-metoxietil)-1Hpirazol-4-il)piridin-4-iloxi)benzo[d]tiazol2-ilamino)ciclohexanol 466.2, 1.89
261
174 (1R,2R)-2-(6-(6’-amino-2,3’-bipiridin-4iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 434.2, 1.78
262
187 (1R,2R)-2-(6-(2-(1H-imidazol-1-il)piridin4-iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 408.2, 1.85
265
174 (1R,2R)-2-(6-(2-(1-metil-1H-pirazol-5il)piridin-4-iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 422.1, 1.93
266
177 (1R,2R)-2-(6-(2-(4,5-dietil-1H-imidazol2-il)piridin-4-iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 464.2, 2.10
48
(cont.)
Comp.
Prep Ej. Estructura Nombre (M+H)+, Tr (min.)
267
177 (1R,2R)-2-(6-(2-(5-metil-4-propil-1Himidazol-2-il)piridin-4iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 464.2, 2.10
280
174 (1R,2R)-2-(6-(2,4’-bipiridin-4iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 419.0, 1.68
281
174 (1R,2R)-2-(6-(2-(1-propil-1H-pirazol-4il)piridin-4-iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 450.0, 2.02
282
174 (1R,2R)-2-(6-(6’-amino-5’(trifluorometil)-2,3’-bipiridin-4iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 502.0, 2.02
283
174 (1R,2R)-2-(6-(2-(1,3,5-trimetil-1Hpirazol-4-il)piridin-4-iloxi)benzo[d]tiazol2-ilamino)ciclohexanol 450.0, 1.86
284
174 (1R,2R)-2-(6-(2-(1H-pirrolo[2,3-b]piridin5-il)piridin-4-iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 458.0, 1.91
285
174 (1R,2R)-2-(6-(2-(pirimidin-5-il)piridin-4iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 420.1, 1.90
286
174 (1R,2R)-2-(6-(2-(2(dimetilamino)pirimidin-5-il)piridin-4iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 463.1, 1.96
49
(cont.)
Comp.
Prep Ej. Estructura Nombre (M+H)+, Tr (min.)
287
174 4-(2-((1R,2R)-2hidroxiciclohexilamino)benzo[d]tiazol-6iloxi)-2,3’-bipiridine-6’-carbonitrile 444.0, 2.18
288
174 (1R,2R)-2-(6-(2-(4-fluorofenil)piridin-4iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 436.0, 2.06
291
195 4-(2-((1R,2R)-2hidroxiciclohexilamino)benzo[d]tiazol-6iloxi)-N-metilnicotinamida 399.1, 1.72
293
162 4-(2-(3hidroxiciclohexilamino)benzo[d]tiazol-6iloxi)-N-metilpicolinamida 399.1, 1.76
320
162 4-(2-((1S,2S)-2hidroxiciclopentilamino)benzo[d]tiazol6-iloxi)-N-metilpicolinamida 385.1, 1.74
322
162 4-(2-((1S,2R)-2hidroxiciclopentilamino)benzo[d]tiazol6-iloxi)-N-metilpicolinamida 385.1, 1.75
324
162 4-(2-((1R,2R)-2hidroxiciclopentilamino)benzo[d]tiazol6-iloxi)-N-metilpicolinamida 385.1, 1.75
344
174 (1R,2R)-2-(6-(2-(1-metil-1H-pirazol-4il)piridin-4-iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 422.2, 1.68
345
174 (1R,2R)-2-(6-(2,3’-bipiridin-4iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 419.1, 1.69
50
(cont.)
Comp.
Prep Ej. Estructura Nombre (M+H)+, Tr (min.)
346
174 (1R,2R)-2-(6-(2-(2-aminopirimidin-5il)piridin-4-iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 435.2, 1.61
359
174 (1R,2R)-2-(6-(2-(1-isobutil-1H-pirazol-4il)piridin-4-iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 464.4, 1.95
360
174 (1R,2R)-2-(6-(2-(1H-pirazol-4-il)piridin4-iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 408.1, 1.63
368
170 (1R,2R)-2-(6-(2-(metilamino)piridin-4iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 371.1, 1.79
369
170 (1R,2R)-2-(6-(2-(etilamino)piridin-4iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 385.1, 1.74
371
175 (1R,2R)-2-(6-(2-(furan-2-il)piridin-4iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 408.1, 1.94
372
175 (1R,2R)-2-(6-(2-(oxazol-2-il)piridin-4iloxi)benzo[d]tiazol-2ilamino)ciclohexanol 409.1, 1.98
376
195 4-(7-bromo-2-((1R,2R)-2hidroxiciclohexilamino)benzo[d]tiazol-6iloxi)-Nmetilpicolinamida 479, 2.37
377
196 4-(2-((1R,2R)-2-hidroxiciclohexilamino)7-metilbenzo[d]tiazol-6-iloxi)-Nmetilpicolinamida 413, 2.09
378
197 4-(7-chloro-2-((1R,2R)-2hidroxiciclohexilamino)benzo[d]tiazol-6iloxi)-Nmetilpicolinamida 433, 2.33
51
imagen64
imagen65
imagen66
imagen67
muestras desconocidas a partir de la curva estándar y expresarse en U/L de Trap5b. La sensibilidad analítica del ensayo es 0.1 U/L y la variación dentro del ensayo y entre los ensayos está por debajo de 10%. Se encontró que los niveles de Trap5b tenían buena correlación con el promedio de puntaje osteolítico (evaluado por rayos x).
Mientras se han descrito en detalle varias realizaciones preferidas de la invención y variaciones de las mismas,
5 otras modificaciones y métodos de uso serán fácilmente evidentes para aquellos expertos en la técnica. De acuerdo con ello, debería entenderse que pueden hacerse diferentes aplicaciones, modificaciones y sustituciones de equivalentes, sin apartarse del espíritu de la invención o del alcance las reivindicaciones.
Las actividades de inhibición porcentuales de los compuestos de las tablas 2 y 3, cuando se prueban a aproximadamente 1µM en el ensayo indicado, como se describe en los Ejemplos biológicos, son mostrados
10 respectivamente en las tablas 5, 6, y 7. Se contempla que los compuestos que tienen una inhibición de 0 % a 1µM exhibirán actividades inhibitorias a una concentración mayor. Un "N/D" indica que el compuesto no fue probado en el ensayo particular.
Tabla 5. Actividades de los compuestos de la tabla 2
Comp.
PDGFRβ CSF-1R cKit M-NFS-60 CP pCSF1R
52
50 100 12 56 71
137
98 100 45 100 98
157
20 100 20 100 99
15 Tabla 6. Actividades de los compuestos de la tabla 3
Comp.
PDGFRβ CSF-1R cKit M-NFS-60 CP pCSF1R
7
9 100 12 35 N/D
10
9 67 0 N/D N/D
11
60 100 0 69 92
12
1 95 0 N/D N/D
13
0 93 9 N/D N/D
14
0 96 3 N/D N/D
15
7 99 15 4 N/D
16
9 99 12 30 N/D
17
12 99 19 23 N/D
18
23 99 80 22 N/D
19
0 96 8 23 N/D
20
0 76 0 N/D N/D
47
4 100 0 55 83
48
16 99 14 26
49
12 100 21 33 77
50
14 99 13 18 N/D
51
0 95 10 N/D N/D
125
9 99 2 17 N/D
155
18 99 34 0 N/D
156
3 100 36 33 N/D
157
17 100 43 42 N/D
56
Cont.
Comp.
PDGFRβ CSF-1R cKit M-NFS-60 CP pCSF1R
158
1 99 27 0 N/D
159
23 100 29 98 96
160
19 100 95 30 N/D
161
26 54 20 N/D N/D
162
30 100 20 100 99
164
87 100 79 100 100
165
83 100 83 100 98
166
0 100 13 49 78
167
0 100 16 24 N/D
168
43 100 40 100 99
169
0 75 12 N/D N/D
170
23 100 28 100 96
171
18 100 25 96 95
172
18 100 22 100 97
173
8 100 18 52 81
174
3 86 18 N/D N/D
175
1 100 11 17 N/D
176
0 63 12 N/D N/D
177
0 67 15 N/D N/D
178
-3 82 17 N/D N/D
179
16 98 10 27 N/D
180
12 100 23 96 93
181
17 72 27 N/D N/D
182
4 100 16 100 98
184
84 100 45 100 95
185
29 100 32 100 94
186
14 100 13 100 99
187
25 100 32 100 98
188
35 100 55 38 N/D
189
23 100 31 26 N/D
190
19 98 22 5 N/D
191
15 45 19 N/D N/D
192
22 99 56 14 N/D
193
15 95 27 0 N/D
194
16 77 20 N/D N/D
195
25 81 90 N/D N/D
196
23 100 29 100 98
57
Cont.
Comp.
PDGFRβ CSF-1R cKit M-NFS-60 CP pCSF1R
197
89 100 93 100 98
200
19 100 29 69 83
203
15 98 22 20 N/D
209
1 100 17 36 N/D
224
0 100 26 33 N/D
225
0 90 21 N/D N/D
226
0 80 20 N/D N/D
231
49 100 9 100 99
232
64 100 34 100 99
258
62 100 44 100 99
259
6 100 24 100 98
260
0 100 25 100 98
261
30 100 25 100 98
262
3 100 20 46 48
265
12 100 9 32 N/D
266
21 100 18 100 94
267
26 100 16 100 96
280
22 100 11 100 65
281
36 100 22 100 96
282
7 99 23 22 N/D
283
20 99 38 0 N/D
284
53 100 61 100 N/D
285
8 99 33 0 N/D
286
0 100 23 71 94
287
20 100 57 35 N/D
288
24 100 78 70 N/D
291
0 48 4 N/D N/D
293
0 100 22 67 82
320
20 100 16 25 N/D
322
11 99 18 21 N/D
324
19 99 21 15 N/D
344
65 100 45 100 95
345
13 100 19 97 93
346
0 100 13 67 84
359
19 100 31 95 93
360
16 100 29 100 98
368
8 100 24 12 N/D
58
imagen68
imagen69
imagen70

Claims (1)

  1. imagen1
    imagen2
    imagen3
    imagen4
    imagen5
    imagen6
    imagen7
    imagen8
    imagen9
    imagen10
    imagen11
    imagen12
    imagen13
    imagen14
ES07797244.6T 2006-04-19 2007-04-18 Compuestos de benzoxazol y benzotiazol sustituidos en 6-O y métodos para inhibir la señalización CSF-1R Active ES2654847T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US79351706P 2006-04-19 2006-04-19
US793517P 2006-04-19
US89385707P 2007-03-08 2007-03-08
US893857P 2007-03-08
PCT/US2007/066898 WO2007121484A2 (en) 2006-04-19 2007-04-18 6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling

Publications (1)

Publication Number Publication Date
ES2654847T3 true ES2654847T3 (es) 2018-02-15

Family

ID=38610468

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07797244.6T Active ES2654847T3 (es) 2006-04-19 2007-04-18 Compuestos de benzoxazol y benzotiazol sustituidos en 6-O y métodos para inhibir la señalización CSF-1R

Country Status (30)

Country Link
US (3) US7553854B2 (es)
EP (1) EP2010528B1 (es)
JP (1) JP5328640B2 (es)
KR (1) KR101464385B1 (es)
AR (1) AR060545A1 (es)
AU (1) AU2007237904B2 (es)
BR (1) BRPI0710540B1 (es)
CA (1) CA2649288C (es)
CR (1) CR10365A (es)
CY (1) CY1119679T1 (es)
DK (1) DK2010528T3 (es)
EA (1) EA018917B1 (es)
EC (1) ECSP088830A (es)
ES (1) ES2654847T3 (es)
HR (1) HRP20171924T1 (es)
HU (1) HUE035654T2 (es)
IL (1) IL194662A0 (es)
LT (1) LT2010528T (es)
MA (1) MA30407B1 (es)
MX (1) MX2008013427A (es)
NO (1) NO20084800L (es)
PE (1) PE20080359A1 (es)
PL (1) PL2010528T3 (es)
PT (1) PT2010528T (es)
RS (1) RS56600B1 (es)
SI (1) SI2010528T1 (es)
SM (1) SMP200800063B (es)
TN (1) TNSN08406A1 (es)
TW (1) TW200813039A (es)
WO (1) WO2007121484A2 (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1499311T3 (da) * 2002-03-29 2010-03-08 Novartis Vaccines & Diagnostic Substituerede benzaboler og anvendelse deraf som RAF-kinaseinhibitorer
WO2007121484A2 (en) * 2006-04-19 2007-10-25 Novartis Ag 6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling
PL2120958T3 (pl) * 2006-12-06 2013-10-31 Univ Central Florida Res Found Inc Inhibitor stat3 posiadający właściwości przeciwnowotworowe i powiązane sposoby
US8293769B2 (en) 2007-05-21 2012-10-23 Novartis Ag CSF-1R inhibitors, compositions, and methods of use
WO2008150015A1 (en) 2007-06-05 2008-12-11 Takeda Pharmaceutical Company Limited Heterobicyclic compounds as kinase inhibitors
JP5270553B2 (ja) * 2007-08-23 2013-08-21 武田薬品工業株式会社 複素環化合物およびその用途
WO2009050228A2 (en) * 2007-10-18 2009-04-23 Novartis Ag Csf-1r inhibitors for treatment of cancer and bone diseases
US20110009421A1 (en) * 2008-02-27 2011-01-13 Takeda Pharmaceutical Company Limited Compound having 6-membered aromatic ring
US8697874B2 (en) 2008-12-01 2014-04-15 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
US8815592B2 (en) 2010-04-21 2014-08-26 Research Development Foundation Methods and compositions related to dopaminergic neuronal cells
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
JP2014505052A (ja) 2011-01-06 2014-02-27 ベータ ファルマ カナダ インコーポレーテッド 癌の治療および予防用の新規なウレア
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
WO2012151541A1 (en) * 2011-05-05 2012-11-08 Novartis Ag Csf-1r inhibitors for treatment of brain tumors
CA2834696C (en) 2011-05-05 2019-07-23 Novartis Ag Csf-1r inhibitors for treatment of brain tumors
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
MX2017004810A (es) 2014-10-14 2017-10-16 Novartis Ag Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas.
MX2017007055A (es) * 2014-12-03 2017-11-08 Genentech Inc Conjugados de anticuerpo rifamicina anti-staphylococcus aureus y usos de estos.
JP6797801B2 (ja) 2014-12-22 2020-12-09 ファイヴ プライム セラピューティクス インク Ｐｖｎｓを治療するための抗ｃｓｆ１ｒ抗体
CN106046007B (zh) * 2015-04-07 2019-02-05 广东众生睿创生物科技有限公司 酪氨酸激酶抑制剂及包含该酪氨酸激酶抑制剂的药物组合物
WO2016182988A1 (en) 2015-05-08 2016-11-17 Memorial Sloan Kettering Cancer Center Compositions and methods for treatment of glioma
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
EP3964528A1 (en) 2015-07-29 2022-03-09 Novartis AG Combination therapies comprising antibody molecules to lag-3
JP2019503349A (ja) 2015-12-17 2019-02-07 ノバルティス アーゲー Ｐｄ−１に対する抗体分子およびその使用
CA3014269A1 (en) * 2016-02-11 2017-08-17 Invictus Oncology Pvt. Ltd. Cellular signalling inhibitors, their formulations and methods thereof
RS65129B1 (sr) 2016-03-28 2024-02-29 Incyte Corp Jedinjenja pirolotriazina kao inhibitori tam
US10689362B2 (en) * 2016-10-10 2020-06-23 Development Center For Biotechnology Quinoxaline compounds as type III receptor tyrosine kinase inhibitors
US10537563B2 (en) 2016-10-14 2020-01-21 Novartis Ag Methods for treating ocular disease using inhibitors of CSF-1R
JP7068288B2 (ja) 2016-10-14 2022-05-16 ノバルティス アーゲー ４－（２－（（１ｒ，２ｒ）－２－ヒドロキシシクロヘキシルアミノ）ベンゾチアゾール－６－イルオキシ）－ｎ－メチルピコリンアミドの結晶形
JP7096817B2 (ja) 2016-11-04 2022-07-06 オークランド ユニサービシーズ リミティド 三環式複素環式誘導体及びその使用
TW201829402A (zh) * 2016-12-23 2018-08-16 美商提薩羅有限公司 群落刺激因子1受體 (csf-1r)之小分子抑制劑及其用途
WO2018146641A1 (en) * 2017-02-11 2018-08-16 Invictus Oncology Pvt. Ltd. Novel inhibitors of cellular signalling
CN110475555A (zh) 2017-03-28 2019-11-19 诺华股份有限公司 治疗多发性硬化的新方法
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
EP3642240A1 (en) 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
SG11201912473PA (en) 2017-06-22 2020-01-30 Novartis Ag Antibody molecules to cd73 and uses thereof
AU2018368731A1 (en) 2017-11-16 2020-05-14 Novartis Ag Combination therapies
CA3084809A1 (en) 2017-12-07 2019-06-13 The Regents Of The University Of Michigan Nsd family inhibitors and methods of treatment therewith
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2020006408A1 (en) 2018-06-29 2020-01-02 Incyte Corporation Formulations of an axl/mer inhibitor
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
CA3123511A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
US20220025036A1 (en) 2018-12-21 2022-01-27 Novartis Ag Use of il-1beta binding antibodies
AU2019409139A1 (en) 2018-12-21 2021-06-03 Novartis Ag Use of IL-1β binding antibodies
WO2020128637A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 binding antibodies in the treatment of a msi-h cancer
EP3903828A4 (en) 2018-12-21 2022-10-05 Daiichi Sankyo Company, Limited COMBINATION OF AN ANTIBODY-DRUG CONJUGATE AND A KINASE INHIBITOR
CA3123519A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2020165833A1 (en) 2019-02-15 2020-08-20 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN114502590A (zh) 2019-09-18 2022-05-13 诺华股份有限公司 Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
CA3165274A1 (en) 2019-12-20 2021-06-24 Novartis Ag Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
CA3180635A1 (en) 2020-04-21 2021-10-28 Novartis Ag Dosing regimen for treating a disease modulated by csf-1r
US11691963B2 (en) 2020-05-06 2023-07-04 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
JP2023531676A (ja) 2020-06-23 2023-07-25 ノバルティス アーゲー ３－（１－オキソイソインドリン－２－イル）ピぺリジン－２，６－ジオン誘導体を含む投与レジメン
WO2022029573A1 (en) 2020-08-03 2022-02-10 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
WO2023009712A1 (en) * 2021-07-29 2023-02-02 Ajax Therapeutics, Inc. Heteroaryloxy thiazolo azines as jak2 inhibitors
US11970494B2 (en) 2021-11-09 2024-04-30 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
WO2024095118A1 (en) 2022-10-31 2024-05-10 Novartis Ag Dosing regimen of a csf-1r inhibitor for use in the treatment of amyotrophic lateral sclerosis

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US4294926A (en) 1979-06-15 1981-10-13 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4319039A (en) 1979-06-15 1982-03-09 Merck & Co., Inc. Preparation of ammonium salt of hypocholesteremic fermentation product
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
JPS5889191A (ja) 1981-11-20 1983-05-27 Sankyo Co Ltd ３−ヒドロキシ−ｍｌ−２３６ｂ誘導体の製造法
AU570021B2 (en) 1982-11-22 1988-03-03 Novartis Ag Analogs of mevalolactone
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4911165A (en) 1983-01-12 1990-03-27 Ethicon, Inc. Pliabilized polypropylene surgical filaments
US4873346A (en) 1985-09-20 1989-10-10 The Upjohn Company Substituted benzothiazoles, benzimidazoles, and benzoxazoles
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
EP0261459A3 (de) 1986-09-09 1988-05-11 Nihon Tokushu Noyaku Seizo K.K. Neue N-Benzothiazolylamide
US4885314A (en) 1987-06-29 1989-12-05 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US4782084A (en) 1987-06-29 1988-11-01 Merck & Co., Inc. HMG-COA reductase inhibitors
US4820850A (en) 1987-07-10 1989-04-11 Merck & Co., Inc. Process for α-C-alkylation of the 8-acyl group on mevinolin and analogs thereof
US5180589A (en) 1988-03-31 1993-01-19 E. R. Squibb & Sons, Inc. Pravastatin pharmaceuatical compositions having good stability
US5030447A (en) 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
US4916239A (en) 1988-07-19 1990-04-10 Merck & Co., Inc. Process for the lactonization of mevinic acids and analogs thereof
US5118853A (en) 1988-10-13 1992-06-02 Sandoz Ltd. Processes for the synthesis of 3-disubstituted aminoacroleins
US5290946A (en) 1988-10-13 1994-03-01 Sandoz Ltd. Processes for the synthesis of 3-(substituted indolyl-2-yl)propenaldehydes
US4929437A (en) 1989-02-02 1990-05-29 Merck & Co., Inc. Coenzyme Q10 with HMG-CoA reductase inhibitors
US5189164A (en) 1989-05-22 1993-02-23 Sandoz Ltd. Processes for the synthesis of syn-(E)-3,5-dihydroxy-7-substituted hept-6-enoic and heptanoic acids and derivatives and intermediates thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
PH27357A (en) 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
US5420245A (en) 1990-04-18 1995-05-30 Board Of Regents, The University Of Texas Tetrapeptide-based inhibitors of farnesyl transferase
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
HU9203780D0 (en) 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
CZ286632B6 (cs) 1992-09-29 2000-05-17 Inhale Therapeutic Systems Farmaceutický prostředek
US5604260A (en) 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
CA2111902A1 (en) 1992-12-21 1994-06-22 Jack Beuford Campbell Antitumor compositions and methods of treatment
EP0764644A1 (en) 1993-01-15 1997-03-26 G.D. Searle & Co. Use of medicaments containing 3,4-diaryl furans and analogs thereof for treating a gastrointestinal condition
WO1994019357A1 (en) 1993-02-23 1994-09-01 Merrell Dow Pharmaceuticals Inc. Farnesyl:protein transferase inhibitors as anticancer agents
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5409944A (en) 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
CA2118985A1 (en) 1993-04-02 1994-10-03 Dinesh V. Patel Heterocyclic inhibitors of farnesyl protein transferase
EP0763537A3 (en) 1993-05-14 1997-10-22 Genentech Inc Non-peptides farnesyl transfer inhibitors
US5602098A (en) 1993-05-18 1997-02-11 University Of Pittsburgh Inhibition of farnesyltransferase
US5380738A (en) 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US5436265A (en) 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
GB9602877D0 (en) 1996-02-13 1996-04-10 Merck Frosst Canada Inc 3,4-Diaryl-2-hydroxy-2,5- dihydrofurans as prodrugs to cox-2 inhibitors
WO1995008542A1 (fr) 1993-09-22 1995-03-30 Kyowa Hakko Kogyo Co., Ltd. Inhibiteur de la farnesyl-transferase
IL111235A (en) 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
SG43768A1 (en) 1993-10-15 1997-11-14 Schering Corp Tricyclic sulfonamide compounds useful for inhibition of g-protein function and for treatment of proliferative dieases
WO1995010515A1 (en) 1993-10-15 1995-04-20 Schering Corporation Tricyclic carbamate compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
US5661152A (en) 1993-10-15 1997-08-26 Schering Corporation Tricyclic sulfonamide compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
EP0725790B1 (en) 1993-10-25 2001-04-18 PARKE DAVIS & COMPANY Substituted tetra- and pentapeptide inhibitors of protein:farnesyl transferase
US5344991A (en) 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
ES2130452T3 (es) 1993-11-04 1999-07-01 Abbott Lab Derivados de ciclobutano utilizados como inhibidores de la escualeno-sintetasa y de la farnesiltransferasa proteica.
NZ275691A (en) 1993-11-05 1998-03-25 Warner Lambert Co Di and tripeptides and compositions thereof which inhibit farnesyl transferase
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5484799A (en) 1993-12-09 1996-01-16 Abbott Laboratories Antifungal dorrigocin derivatives
US5393790A (en) 1994-02-10 1995-02-28 G.D. Searle & Co. Substituted spiro compounds for the treatment of inflammation
WO1995024612A1 (de) 1994-03-07 1995-09-14 International Business Machines Corporation Verfahren und vorrichtung zur schnellen interpolation von zwischenwerten aus periodischen phasenverschobenen signalen und zur erkennung von defekten in einem drehkörper
JP3969737B2 (ja) 1994-03-15 2007-09-05 エーザイ株式会社 イソプレニルトランスフェラーゼ阻害剤
IL113196A0 (en) 1994-03-31 1995-06-29 Bristol Myers Squibb Co Imidazole derivatives and pharmaceutical compositions containing the same
US5523430A (en) 1994-04-14 1996-06-04 Bristol-Myers Squibb Company Protein farnesyl transferase inhibitors
US5510510A (en) 1994-05-10 1996-04-23 Bristol-Meyers Squibb Company Inhibitors of farnesyl protein transferase
US5563255A (en) 1994-05-31 1996-10-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
PL317580A1 (en) 1994-06-10 1997-04-14 Rhone Poulenc Rorer Sa Novel inhibitors of farnesil transferase, method of obtaining them and pharmaceutic compositions containing such inhibitors
US5571792A (en) 1994-06-30 1996-11-05 Warner-Lambert Company Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase
WO1996005529A1 (en) 1994-08-09 1996-02-22 Micron Optics, Inc. Temperature compensated fiber fabry-perot filters
ATE188464T1 (de) 1994-08-11 2000-01-15 Banyu Pharma Co Ltd Substituierte amidderivate
CA2155448A1 (en) 1994-08-11 1996-02-12 Katerina Leftheris Inhibitors of farnesyl protein transferase
EP0805154A1 (en) 1994-08-12 1997-11-05 Banyu Pharmaceutical Co., Ltd. N,n-disubstituted amic acid derivative
DE4429506B4 (de) 1994-08-19 2007-09-13 Degussa Gmbh Verfahren zur Extraktion natürlicher Carotinoid-Farbstoffe
DE4429653C2 (de) 1994-08-20 1997-04-03 Anton Dr More Konverter und Verfahren zum Frischen von Metallschmelzen insbesondere von Roheisen zu Stahl
WO1996016443A1 (en) 1994-11-22 1996-05-30 Philips Electronics N.V. Semiconductor device with a carrier body on which a substrate with a semiconductor element is fastened by means of a glue layer and on which a pattern of conductor tracks is fastened
WO1996017861A1 (en) 1994-12-09 1996-06-13 Warner-Lambert Company Substituted tetra- and pentapeptide inhibitors of protein:farnesyl transferase
CA2211017A1 (en) 1995-01-09 1996-07-18 Magla International Ltd. Wear resistant image printing on latex surfaces
EP0794789A4 (en) 1995-01-12 1999-05-26 Univ Pittsburgh PRENYL TRANSFERASE INHIBITORS
FR2729390A1 (fr) 1995-01-18 1996-07-19 Rhone Poulenc Rorer Sa Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
US6020343A (en) 1995-10-13 2000-02-01 Merck Frosst Canada, Inc. (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
DE59609305D1 (de) 1995-11-17 2002-07-11 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Herstellung
PT1288206E (pt) 1996-04-12 2008-11-14 Searle Llc Derivados de benzenossulfonamida substituídos como pró-fármacos de inibidores de cox-2
US5861419A (en) 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
JP4579351B2 (ja) 1996-12-03 2010-11-10 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ エポチロンの合成とその中間体及びその類似物並びにその使用
HU228193B1 (en) 1997-10-08 2013-01-28 Sankyo Co Imidazole fused heterocyclic compounds, process for their preparation, pharmaceutical compositions containing the same and their use
SK286213B6 (sk) 1997-12-22 2008-05-06 Bayer Corporation Substituované heterocyklické močoviny, farmaceutický prípravok ich obsahujúci a ich použitie
JP4169450B2 (ja) 1999-04-07 2008-10-22 第一三共株式会社 インスリン抵抗性改善剤
KR20010110750A (ko) 1999-04-12 2001-12-13 앤드류 앵뉴 인테그린 길항제로서의 치환된 비사이클릭 헤테로아릴화합물
AU777275B2 (en) 1999-07-02 2004-10-07 Stuart A. Lipton Method of reducing neuronal injury or apoptosis
EP1341771A2 (en) 2000-11-29 2003-09-10 Glaxo Group Limited Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
AUPR213700A0 (en) 2000-12-18 2001-01-25 Biota Scientific Management Pty Ltd Antiviral agents
BR0208956A (pt) 2001-04-16 2004-07-13 Tanabe Seiyaku Co Abridor de canais de k ativados por cálcio de grande condutância
US7642278B2 (en) 2001-07-03 2010-01-05 Novartis Vaccines And Diagnostics, Inc. Indazole benzimidazole compounds
DK1499311T3 (da) 2002-03-29 2010-03-08 Novartis Vaccines & Diagnostic Substituerede benzaboler og anvendelse deraf som RAF-kinaseinhibitorer
US8299108B2 (en) 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
EP1535910A4 (en) 2002-05-01 2007-03-14 Kirin Brewery CHINOLINE DERIVATIVES AND CHINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORILATION OF THE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR
EP1717220A3 (en) 2002-08-08 2007-08-22 Amgen, Inc Vanilloid receptor ligands and their use in treatments
ATE552253T1 (de) 2002-11-08 2012-04-15 Novartis Int Pharm Ltd 3-substituierte-6-aryl- pyridin derivate als liganden für c5a-rezeptoren
DE10306250A1 (de) 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7531553B2 (en) 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
SI2213661T1 (sl) * 2003-09-26 2011-11-30 Exelixis Inc c-Met modulatorji in postopki uporabe
CA2542653A1 (en) 2003-10-16 2005-04-28 Chiron Corporation Substituted benzazoles and use thereof as inhibitors of raf kinase
KR20060105872A (ko) 2003-12-29 2006-10-11 반유 세이야꾸 가부시끼가이샤 신규한 2-헤테로아릴 치환된 벤즈이미다졸 유도체
CA2553433A1 (en) * 2004-01-23 2005-08-11 Amgen Inc. Quinoline quinazoline pyridine and pyrimidine compounds and their use in the treatment of inflammation angiogenesis and cancer
JP2007535565A (ja) 2004-04-30 2007-12-06 バイエル ファーマシューティカルス コーポレーション 癌の治療に有用な置換ピラゾリル尿素誘導体
EP1753428A4 (en) 2004-05-14 2010-09-15 Abbott Lab INHIBITORS OF KINASES AS THERAPEUTIC AGENTS
BRPI0511741A (pt) 2004-06-04 2008-01-02 Astrazeneca Ab derivado de quinazolina ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, processo para a preparação de um derivado de quinazolina ou de um sal farmaceuticamente aceitável do mesmo
MXPA06014909A (es) 2004-06-18 2007-02-28 Chiron Corp Derivados de n-(1-(1-bencil -4-fenil-1h -imidazol -2-il)-2, 2-dimetilpropil) benzamida y compuestos relacionados como inhibidores de proteina de huso de cinesina (ksp) para el tratamiento del cancer.
WO2007121484A2 (en) * 2006-04-19 2007-10-25 Novartis Ag 6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling

Also Published As

Publication number Publication date
US20120225861A1 (en) 2012-09-06
IL194662A0 (en) 2009-08-03
EP2010528A2 (en) 2009-01-07
SI2010528T1 (en) 2018-02-28
US20080045528A1 (en) 2008-02-21
CR10365A (es) 2009-01-07
US8710048B2 (en) 2014-04-29
BRPI0710540A2 (pt) 2012-01-31
WO2007121484A3 (en) 2008-02-07
SMP200800063B (it) 2009-11-06
US7553854B2 (en) 2009-06-30
RS56600B1 (sr) 2018-02-28
US20100280006A1 (en) 2010-11-04
HUE035654T2 (en) 2018-05-28
JP5328640B2 (ja) 2013-10-30
MX2008013427A (es) 2008-11-04
HRP20171924T1 (hr) 2018-02-09
TNSN08406A1 (en) 2010-04-14
MA30407B1 (fr) 2009-05-04
EA018917B1 (ru) 2013-11-29
PL2010528T3 (pl) 2018-03-30
CA2649288A1 (en) 2007-10-25
BRPI0710540B1 (pt) 2022-04-12
PE20080359A1 (es) 2008-06-06
WO2007121484A2 (en) 2007-10-25
KR101464385B1 (ko) 2014-11-21
US8173689B2 (en) 2012-05-08
CY1119679T1 (el) 2018-04-04
PT2010528T (pt) 2017-12-21
SMAP200800063A (it) 2008-11-19
TW200813039A (en) 2008-03-16
AR060545A1 (es) 2008-06-25
EA200802129A1 (ru) 2009-04-28
JP2009534410A (ja) 2009-09-24
NO20084800L (no) 2008-11-17
ECSP088830A (es) 2008-11-27
LT2010528T (lt) 2017-12-27
CA2649288C (en) 2015-11-24
AU2007237904A1 (en) 2007-10-25
KR20080112388A (ko) 2008-12-24
DK2010528T3 (en) 2018-01-15
AU2007237904B2 (en) 2011-03-03
EP2010528B1 (en) 2017-10-04

Similar Documents

Publication Publication Date Title
ES2654847T3 (es) Compuestos de benzoxazol y benzotiazol sustituidos en 6-O y métodos para inhibir la señalización CSF-1R
RU2424240C2 (ru) Антибактериальные производные пиперидина
Kumar et al. New structural classes of antituberculosis agents
HUE030787T2 (en) Substituted piperidines as CCR3 antagonists
HRP20151435T1 (hr) Diamino heterociklički karboksamidni spoj
RU2417223C2 (ru) Оксазолидиноновые производные, способ их получения (варианты) и фармацевтическая композиция на их основе
BR112012017713A2 (pt) Aminopiridina, formulação farmacêutica, processo para a preparação de um derivado de aminopiridina, intermediário, e, uso de uma aminopiridina ou de uma formulação farmacêutica
CA2628844A1 (en) Pyrazole derivatives and their medical use
CA3014572A1 (en) Acid addition salts of piperazine derivatives
RU2012134306A (ru) Азотосодержащие производные гетероарилов
JP2017525757A5 (es)
WO2004087153A2 (en) Use of organic compounds for immunopotentiation
JP2013539777A5 (es)
RU2013143028A (ru) Тиазолилфенилбензолсульфонамидопроизводные в качестве ингибиторов киназ
RU2011116226A (ru) Пиразолопиридиновые производные как ингибиторы надфн-оксидазы
EP3313842B1 (en) Pyrazolo[1,5-a]triazin-4-amine derivatives useful in therapy
RU2010110640A (ru) Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ
JP2006500348A5 (es)
RU2005102098A (ru) Амидное производное
RU2008116828A (ru) Комбинированный метод терапии замещенными оксазолидинонами для профилактики и лечения нарушений церебрального местного кровообращения
RU2013138834A (ru) N-[3-(5-амино-3,3а,7,7а-тетрагидро-1н-2,4-диокса-6-аза-инден-7-ил)-фенил]-амиды в качестве ингибиторов васе1 и(или) васе2
RU2008135690A (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
HRP20120748T1 (hr) Heterocikliäśki spoj i farmaceutski sastavi koji ga sadrže
JP2010540462A5 (es)
CA2737999A1 (en) Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma